NEW YORK, Nov. 14, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ: DVAX). Such investors are advised to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/dvax.
The investigation concerns whether Dynavax and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On November 14, 2016, Dynavax dropped over 62% on intraday trading after Dynavax announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration, requesting additional information "including clarification regarding specific adverse events of special interest (AESIs), a numerical imbalance in a small number of cardiac events in a single study (HBV-23), new analyses of the integrated safety data base across different time periods, and post-marketing commitments."
If you are aware of any facts relating to this investigation, or purchased Dynavax shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/dvax. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.